Neurochemical and some related psychopharmacological aspects of Tourette's syndrome: an update

Neurochemical investigations of Tourette's syndrome (TS) suggest that the symptoms of this disorder may be the result of an imbalance among several neurotransmitter and/or neuromodulator systems. Neurochemicals which have been studied included: catecholamines; acetylcholine; tryptophan and its metabolites; the amino acids γ-aminobutyric acid (GABA), glutamate, phenylalanine and p-tyrosine; trace amines; opioid peptides; cyclic AMP and androgenic hormones. A suitable animal model of TS would do much to advance our understanding of this disorder, and there are some interesting recent developments in this regard.

[1]  R. Landgraf,et al.  Neuroendocrine and behavioral effects of antisense oligonucleotides. , 1997, European journal of endocrinology.

[2]  R. Bornstein,et al.  Obsessive-Compulsive Symptom Clusters and Urinary Amine Correlates in Tourette Syndrome , 1995, The Journal of nervous and mental disease.

[3]  D. Curtis,et al.  Exclusion of the 5-HT1A serotonin neuroreceptor and tryptophan oxygenase genes in a large British kindred multiply affected with Tourette's syndrome, chronic motor tics, and obsessive-compulsive behavior. , 1995, The American journal of psychiatry.

[4]  A. Straube,et al.  Blunted growth hormone response to clonidine in Gilles de la Tourette Syndrome , 1994, Psychoneuroendocrinology.

[5]  R. Hen,et al.  5-Hydroxytryptamine receptor subtypes in vertebrates and invertebrates , 1994, Neurochemistry International.

[6]  L. Regeur,et al.  Pharmacological Treatment of Gilles de la Tourette’s Syndrome , 1994 .

[7]  G. Sawle,et al.  PET studies of the presynaptic and postsynaptic dopaminergic system in Tourette's syndrome. , 1994, Journal of neurology, neurosurgery, and psychiatry.

[8]  Micaela Morelli,et al.  Modulatory functions of neurotransmitters in the striatum: ACh/dopamine/NMDA interactions , 1994, Trends in Neurosciences.

[9]  R. T. Jackson,et al.  Active [3H]-dopamine uptake by human lymphocytes: correlates with serotonin transporter activity. , 1994, Pharmacology.

[10]  D. Brooks,et al.  Tourette's syndrome and the opioid system , 1994, The Lancet.

[11]  C. McDougle,et al.  Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. , 1994, Archives of general psychiatry.

[12]  K. Kidd,et al.  D2 dopamine receptor alleles do not influence severity of Tourette's syndrome. Results from four large kindreds. , 1994, Archives of neurology.

[13]  C. J. Schmidt,et al.  Blockade of Striatal 5‐Hydroxytryptmine2 Receptors Reduces the Increase in Extracellullar Concentrations of Dopamine Produced by the Amphhetamine analogue 3,4‐Methylenedioxymethamphetamine , 1994, Journal of neurochemistry.

[14]  P. Chappell.  Sequential use of opioid antagonists and agonists in Tourette's syndrome , 1994, The Lancet.

[15]  W. Freed.  Glutamatergic mechanisms mediating stimulant and antipsychotic drug effects , 1994, Neuroscience & Biobehavioral Reviews.

[16]  O. Suchowersky.  Gilles de la Tourette Syndrome – Review Article , 1994, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[17]  S. Dursun,et al.  Complex of rapid movements and vocalization induced by RX336-M in mice: possible relevance to Tourette's syndrome , 1994, Journal of psychopharmacology.

[18]  K. Perry,et al.  Possible involvement of dopamine in the long-term serotonin depletion by p-chloroamphetamine and beta,beta-difluoro-p-chloroamphetamine in rats. , 1993, The Journal of pharmacology and experimental therapeutics.

[19]  M. Trimble,et al.  Fluvoxamine and sulpiride in comorbid obsessive–compulsive disorder and gilles de la tourette syndrome , 1993 .

[20]  X. Huang,et al.  5-HT2 receptor-mediated potentiation of dopamine synthesis and central serotonergic deficits. , 1993, European journal of pharmacology.

[21]  A. Silver,et al.  Transdermal nicotine patch and potentiation of haloperidol in Tourette's syndrome , 1993, The Lancet.

[22]  M. Nöthen,et al.  Tourette's syndrome and homozygosity for the dopamine D3 receptor gene , 1993, The Lancet.

[23]  M. Mercugliano.  Psychopharmacology in children with developmental disabilities. , 1993, Pediatric clinics of North America.

[24]  D. Cohen,et al.  Neuroendocrine and behavioral effects of the selective kappa agonist spiradoline in Tourette's syndrome: A pilot study , 1993, Psychiatry Research.

[25]  W. Hewlett.  The Use of Benzodiazepines in Obsessive Compulsive Disorder and Tourette's Syndrome , 1993 .

[26]  H. Gurling,et al.  Failure to find linkage and increased homozygosity for the dopamine D3 receptor gene in Tourette's syndrome , 1993, The Lancet.

[27]  F. Mora,et al.  Effects of amphetamine on the release of excitatory amino acid neurotransmitters in the basal ganglia of the conscious rat. , 1993, Canadian journal of physiology and pharmacology.

[28]  D. Comings,et al.  Association between Tourette's syndrome and homozygosity at the dopamine D3 receptor gene , 1993, The Lancet.

[29]  P. Sandor,et al.  Gilles de la Tourette syndrome: a neuropsychiatric disorder. , 1993, Journal of psychosomatic research.

[30]  J. Jankovic,et al.  Deprenyl in attention deficit associated with Tourette's syndrome. , 1993, Archives of neurology.

[31]  P. Bieck,et al.  The ‘serotonin/norepinephrine link’ beyond the β adrenoceptor , 1992 .

[32]  B. Peterson,et al.  Steroid hormones and CNS sexual dimorphisms modulate symptom expression in tourette's syndrome , 1992, Psychoneuroendocrinology.

[33]  C. Adler,et al.  Tourette's syndrome. Current approaches to recognition and management. , 1992, Postgraduate medicine.

[34]  T. Insel,et al.  Toward a neuroanatomy of obsessive-compulsive disorder. , 1992, Archives of general psychiatry.

[35]  R. Bornstein,et al.  Urinary amines in adults with tourette's syndrome , 1992, Psychiatry Research.

[36]  M. Javors,et al.  Neurochemistry and child and adolescent psychiatry. , 1992, Journal of the American Academy of Child and Adolescent Psychiatry.

[37]  T. Sharp,et al.  Evidence that 5‐HT2 receptor activation decreases noradrenaline release in rat hippocampus in vivo , 1992, British journal of pharmacology.

[38]  R. Kahn,et al.  Functional interrelationship of serotonin and norepinephrine: Cortisol response to MCPP and DMI in patients with panic disorder, patients with depression, and normal control subjects , 1992, Psychiatry Research.

[39]  A. Korczyn,et al.  Decreased (3H) quinuclidinyl benzilate binding to lymphocytes in Gilles de la Tourette syndrome , 1992, Biological Psychiatry.

[40]  S. Handley,et al.  Serotonin and Tourettes syndrome Movements such as head-shakes and wet-dog shakes may model human tics , 1992 .

[41]  J. Tillement,et al.  Serotonin enhances the β-adrenergic response in rat brain cortical slices , 1992 .

[42]  R. Bornstein,et al.  Urinary indoleamines in Tourette syndrome patients with obsessive-compulsive characteristics , 1992, Psychiatry Research.

[43]  H. Singer,et al.  Abnormal dopamine uptake sites in postmortem striatum from patients with tourette's syndrome , 1991, Annals of neurology.

[44]  G. S. Mudholkar,et al.  A controlled trial of propoxyphene and naltrexone in patients with tourette's syndrome , 1991, Annals of neurology.

[45]  B. Meldrum.  Excitatory Amino Acid Transmitters in Epilepsy , 1991, Epilepsia.

[46]  D. Cohen,et al.  Clonidine treatment of Gilles de la Tourette's syndrome. , 1991, Archives of general psychiatry.

[47]  R. Bornstein,et al.  Phenylethylaminergic mechanisms in attention-deficit disorder , 1991, Biological Psychiatry.

[48]  H. Singer,et al.  Tourette Syndrome and Other Tic Disorders Diagnosis, Pathophysiology, and Treatment , 1991, Medicine.

[49]  A. Boulton,et al.  2‐Phenylethylamine: A Modulator of Catecholamine Transmission in the Mammalian Central Nervous System? , 1990, Journal of neurochemistry.

[50]  R. Bornstein,et al.  Urinary excretion of metabolites of norepinephrine in Tourette's syndrome. , 1990, Molecular and chemical neuropathology.

[51]  W. Goodman,et al.  Fluvoxamine/Pimozide Treatment of Concurrent Tourette's and Obsessive-Compulsive Disorder , 1990, British Journal of Psychiatry.

[52]  D. Comings,et al.  Blood serotonin and tryptophan in Tourette syndrome. , 1990, American journal of medical genetics.

[53]  J. Leckman,et al.  Possible exacerbation of tics by androgenic steroids. , 1990, The New England journal of medicine.

[54]  A. Lees,et al.  Management of Gilles de la Tourette syndrome using sulpiride. , 1990, Clinical neuropharmacology.

[55]  H. Singer,et al.  Tourette's syndrome: A neurochemical analysis of postmortem cortical brain tissue , 1990, Annals of neurology.

[56]  D. Comings.  Tourette Syndrome and Human Behavior , 1990 .

[57]  R. Bornstein,et al.  Urinary amines in Tourette's syndrome patients with and without phenylethylamine abnormality , 1990, Psychiatry Research.

[58]  A. Shapiro,et al.  Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette's syndrome. , 1989, Archives of general psychiatry.

[59]  M. Robertson.  The Gilles de la Tourette Syndrome: the Current Status , 1989, British Journal of Psychiatry.

[60]  R. Kurlan,et al.  Opiate withdrawal unmasks Tourette's syndrome. , 1988, Clinical neuropharmacology.

[61]  F. Messiha.  Biochemical pharmacology of Gilles de la Tourette's syndrome , 1988, Neuroscience & Biobehavioral Reviews.

[62]  G. S. Golden,et al.  The relationship between stimulant medication and tics. , 1988, Pediatric annals.

[63]  M. Trimble,et al.  The Psychopathology of the Gilles de la Tourette Syndrome , 1988, British Journal of Psychiatry.

[64]  S. Sivam,et al.  Regulation of the concentration of dynorphin A1–8 in the striatonigral pathway by the dopaminergic system , 1986, Brain Research.

[65]  L. Siever,et al.  Blunted growth hormone response to clonidine in panic disorder patients , 1986, Biological Psychiatry.

[66]  J. C. Stoof,et al.  Blockade of D-2 dopamine receptors strongly enhances the potency of enkephalins to inhibit dopamine-sensitive adenylate cyclase in rat neostriatum: involvement of delta- and mu-opioid receptors , 1986, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[67]  D. Benson,et al.  Obsessions and compulsions in Gilles de la Tourette's syndrome , 1986, Neurology.

[68]  K. Merikangas,et al.  Blood choline and response to clonazepam and haloperidol in Tourette's syndrome , 1985, Acta psychiatrica Scandinavica.

[69]  R. Sandyk.  The effects of naloxone in tourette's syndrome , 1985, Annals of neurology.

[70]  R. Quirion,et al.  Possible interactions between dynorphin and dopaminergic systems in rat basal ganglia and substantia nigra , 1985, Brain Research.

[71]  Carl-Eric Kaiser,et al.  Dopamine receptors: Functions, subtypes and emerging concepts , 1985, Medicinal research reviews.

[72]  J. Coyle,et al.  CSF cholinesterase activity in Gilles de la Tourette's syndrome. , 1984, Archives of neurology.

[73]  J. Rapoport,et al.  Phenylethylamine excretion in attention deficit disorder. , 1984, Journal of the American Academy of Child Psychiatry.

[74]  D. Cohen,et al.  A new instrument for clinical studies of Tourette's syndrome. , 1984, Journal of the American Academy of Child Psychiatry.

[75]  R. Bruun.  An Overview of Clinical Experience , 1984 .

[76]  R. Spiegel.  Effects of RS 86, an orally active cholinergic agonist, on sleep in man , 1984, Psychiatry Research.

[77]  B. Shaywitz,et al.  Acute and Chronic CLonidine Treatment in Tourette's Syndrome , 1983 .

[78]  E. Costa,et al.  Adenylate cyclase activity of synaptic membranes from rat striatum. Inhibition by muscarinic receptor agonists. , 1983, Molecular pharmacology.

[79]  J. Davis,et al.  Reduced excretion of MHPG in Tourette syndrome. , 1982, Advances in neurology.

[80]  J. Coyle,et al.  Dopaminergic dysfunction in tourette syndrome , 1982 .

[81]  D. Cooper,et al.  Opiate Receptor‐Mediated Inhibition of Adenylate Cyclase in Rat Striatal Plasma Membranes , 1982, Journal of neurochemistry.

[82]  R. Tissot,et al.  gamma-Aminobutyric acid (GABA) receptor stimulation. III. Effect of progabide (SL 76002) on norepinephrine, dopamine and 5-hydroxytryptamine turnover in rat brain areas. , 1982, The Journal of pharmacology and experimental therapeutics.

[83]  A. Juorio.  The effects of some antipsychotic drugs, D-amphetamine, and reserpine on the concentration and rate of accumulation of tryptamine and 5-hydroxytryptamine in the mouse striatum. , 1982, Canadian journal of physiology and pharmacology.

[84]  B. Scatton,et al.  gamma-Aminobutyric acid (GABA) receptor stimulation. IV. Effect of progabide (SL 76002) and other GABAergic agents on acetylcholine turnover in rat brain areas. , 1982, The Journal of pharmacology and experimental therapeutics.

[85]  B. Shaywitz,et al.  Stimulant medications precipitate Tourette's syndrome. , 1982, JAMA.

[86]  Z. Selinger.  MECHANISMS OF ADENYLATE CYCLASE ACTIVATION , 1981 .

[87]  Stahl Sm,et al.  Physostigmine in Tourette syndrome: evidence for cholinergic underactivity. , 1981, The American journal of psychiatry.

[88]  R. Caprioli,et al.  Biogenic amine metabolism in tourette syndrome , 1979, Annals of neurology.

[89]  J. Nathanson,et al.  Central biogenic amine metabolism in children with the syndrome of chronic multiple tics of Gilles de la Tourette: norepinephrine, serotonin, and dopamine. , 1979, Journal of the American Academy of Child Psychiatry.

[90]  W. Weiner,et al.  Gilles de la Tourette syndrome after long‐term chlorpromazine therapy , 1978, Neurology.

[91]  H. Moldofsky,et al.  A comparison of pimozide and haloperidol in the treatment of Gilles de la Tourette's syndrome. , 1978, The American journal of psychiatry.

[92]  D. Pickar,et al.  NORADRENERGIC AND DOPAMINERGIC MECHANISMS IN GILLES DE LA TOURETTE SYNDROME , 1978, The Lancet.

[93]  B. Shaywitz,et al.  Chronic, multiple tics of Gilles de la Tourette's disease. CSF acid monoamine metabolites after probenecid administration. , 1978, Archives of general psychiatry.

[94]  S H Snyder,et al.  The opiate receptor. , 1975, Neurosciences Research Program bulletin.

[95]  R. Bruun,et al.  Presynaptic catecholamine antagonists as treatment for Tourette syndrome. Effects of alpha methyl para tyrosine and tetrabenazine. , 1974, Archives of general psychiatry.

[96]  C. McDougle,et al.  Cerebrospinal Fluid Biogenic Amines in Obsessive Compulsive Disorder, Tourette's Syndrome, and Healthy Controls , 1995, Neuropsychopharmacology.

[97]  T. Betts,et al.  Elevated plasma kynurenine in Tourette syndrome. , 1994, Molecular and chemical neuropathology.

[98]  M Farrell,et al.  Opiate withdrawal. , 1994, Addiction.

[99]  R. Kurlan,et al.  Tourette's syndrome and nicotine withdrawal. , 1993, The Journal of neuropsychiatry and clinical neurosciences.

[100]  J. Elia.  Drug treatment for hyperactive children. Therapeutic guidelines. , 1993, Drugs.

[101]  M. Trimble,et al.  Obsessions in obsessive-compulsive disorder with and without Gilles de la Tourette's syndrome. , 1993, The American journal of psychiatry.

[102]  A. Pakstis,et al.  Exclusion of close linkage of Tourette's syndrome to D1 dopamine receptor. , 1993, The American journal of psychiatry.

[103]  C. Cotman,et al.  Excitatory amino acid receptors in schizophrenia. , 1993, Schizophrenia bulletin.

[104]  H. Singer.  Tic disorders. , 1993, Pediatric annals.

[105]  R. Bornstein,et al.  Urinary excretion of MHPG and normetanephrine in attention deficit hyperactivity disorder. , 1993, Molecular and chemical neuropathology.

[106]  B. Peterson,et al.  Pathogenesis of Tourette syndrome. Clues from the clinical phenotype and natural history. , 1992, Advances in neurology.

[107]  S. Haber,et al.  Basal ganglia peptidergic staining in Tourette syndrome. A follow-up study. , 1992, Advances in neurology.

[108]  G. Sawle,et al.  PET studies on the integrity of the pre and postsynaptic dopaminergic system in Tourette syndrome. , 1992, Advances in neurology.

[109]  C. Goetz.  Clonidine and clonazepam in Tourette syndrome. , 1992, Advances in neurology.

[110]  P. Bieck,et al.  The 'serotonin/norepinephrine link' beyond the beta adrenoceptor. , 1992, Brain research. Molecular brain research.

[111]  J. Tillement,et al.  Serotonin enhances the beta-adrenergic response in rat brain cortical slices. , 1992, European journal of pharmacology.

[112]  D. Cohen,et al.  Postmortem analysis of subcortical monoamines and amino acids in Tourette syndrome. , 1992, Advances in neurology.

[113]  E. J. Colon,et al.  Methadone treatment of Tourette's disorder. , 1992, The American journal of psychiatry.

[114]  D. Cohen,et al.  Neuroendocrine and behavioral effects of naloxone in Tourette syndrome. , 1992, Advances in neurology.

[115]  LeWitt Pa.  Therapeutics of Tourette syndrome. New medication approaches. , 1992 .

[116]  H. Singer,et al.  Positron emission tomography evaluation of dopamine D-2 receptors in adults with Tourette syndrome. , 1992, Advances in neurology.

[117]  H. Singer.  Neurochemical analysis of postmortem cortical and striatal brain tissue in patients with Tourette syndrome. , 1992, Advances in neurology.

[118]  Baker Gb,et al.  Neuropsychological performance and urinary phenylethylamine in Tourette's syndrome. , 1991 .

[119]  R. Bornstein,et al.  Phenylethylamine metabolism in Tourette's syndrome. , 1990, The Journal of neuropsychiatry and clinical neurosciences.

[120]  A. Juorio,et al.  Tryptamine may couple dopaminergic and serotonergic transmission in the brain. , 1990, General pharmacology.

[121]  S. Peroutka.  5-Hydroxytryptamine receptor subtypes. , 1990, Pharmacology & toxicology.

[122]  C. Nemeroff,et al.  Elevated CSF dynorphin A [1-8] in Tourette's syndrome. , 1988, Life sciences.

[123]  P. Wood,et al.  Tryptamine Turnover: Effects of Drugs , 1988 .

[124]  M. Mesulam,et al.  Clinical comparison of Tourette's disorder and obsessive-compulsive disorder. , 1987, The American journal of psychiatry.

[125]  J. Obeso,et al.  Coprolalia associated with hemiballismus: response to tetrabenazine. , 1985, Clinical neuropharmacology.

[126]  Martí-Massó Jf,et al.  Coprolalia associated with hemiballismus: response to tetrabenazine. , 1985 .

[127]  R. Bruun.  Gilles de la Tourette's syndrome. An overview of clinical experience. , 1984, Journal of the American Academy of Child Psychiatry.

[128]  H. Hendrie,et al.  Effect of Chronic Haloperidol on the Levels of Blood and Urinary Phenylethylamine and Phenylacetic Acid in Rats , 1984 .

[129]  B. Shaywitz,et al.  Acute and chronic clonidine treatment in Tourette's syndrome: a preliminary report on clinical response and effect on plasma and urinary catecholamine metabolites, growth hormone, and blood pressure. , 1983, Journal of the American Academy of Child Psychiatry.

[130]  Koslow Sh,et al.  Cerebrospinal fluid monoamine metabolites in Tourette syndrome and their neuroendocrine implications. , 1982 .

[131]  A. Boulton,et al.  Brain Trace Amines , 1982 .

[132]  Z. A. Trapeznikova.  On the Interaction of , 1959 .